Condition: HER2-positive Advanced Solid Tumors · Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
To evaluate the safety and tolerability of SPH5030 tablets in subjects with HER2-positive advanced solid tumors
This description comes directly from the study's public registry record.
Xingchen Wang · +8615811589825 · wangxc@sphchina.com
Always discuss trial participation with your own doctor first.
| Anhui provincial hospital | Hefei, Anhui, China | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Guangxi Cancer Hospital | Nanning, Guangxi, China | Recruiting |
| The Fourth Hospital of Hebei Medical University | Shijiazhuang, Hebei, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| Anyang Cancer Hospital | Anyang, Henan, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| Xiangyang Central Hospital | Xiangyang, Hubei, China | Recruiting |
| Jiangsu Province Hospital | Nanjing, Jiangsu, China | Recruiting |
| The First Affiliated Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
| Linyi Cancer Hospital | Linyi, Shandong, China | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05245058